Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

Hagop M. Kantarjian, Harry P. Erba, David Claxton, Martha Arellano, Roger M. Lyons, Tibor Kovascovics, Janice Gabrilove, Michael Craig, Dan Douer, Michael Maris, Stephen Petersdorf, Paul J. Shami, Andrew M Yeager, Stephen Eckert, Rekha Abichandani, Stefan Faderl

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Purpose: This phase II study assessed clofarabine monotherapy in older adults (≥ 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. Patients and Methods: Clofarabine was administered intravenously for 5 days at 30 mg/m2/d during induction and 20 mg/m2/d during reinduction/consolidation (six cycles maximum). The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Results: In 112 evaluable patients who were treated (median age, 71 years; range, 60 to 88 years), the ORR was 46% (38% CR, 8% CRp). ORR by unfavorable prognostic factor was 39% for patients ≥ 70 years of age; 32% for Eastern Cooperative Oncology Group (ECOG) performance status 2; 51% for antecedent hematologic disorder; 54% for intermediate karyotype; 42% for unfavorable karyotype; and 48%, 51%, and 38% for one, two, and three risk factors, respectively. The median disease-free survival was 37 weeks (95% CI, 26 to 56 weeks). Median duration of remission was 56 weeks (95% CI, 33 to not estimable). The estimated median overall survival was 41 weeks (95% CI, 28 to 53 weeks) for all patients, 59 weeks for patients with CR/CRp, and 72 weeks for patients with CR. The 30-day all-cause mortality was 9.8%. The most common non-laboratory drug-related toxicities (≥ 20% patients) were nausea, febrile neutropenia, vomiting, diarrhea, rash, and fatigue. Conclusion: Clofarabine is an active agent with acceptable toxicity in patients age 60 years or older with untreated AML who have at least one unfavorable prognostic factor. ORR did not seem affected by the presence of multiple unfavorable prognostic factors.

Original languageEnglish (US)
Pages (from-to)549-555
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number4
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Karyotype
Febrile Neutropenia
clofarabine
Exanthema
Drug-Related Side Effects and Adverse Reactions
Nausea
Disease-Free Survival
Vomiting
Fatigue
Diarrhea
Blood Platelets
Survival
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. / Kantarjian, Hagop M.; Erba, Harry P.; Claxton, David; Arellano, Martha; Lyons, Roger M.; Kovascovics, Tibor; Gabrilove, Janice; Craig, Michael; Douer, Dan; Maris, Michael; Petersdorf, Stephen; Shami, Paul J.; Yeager, Andrew M; Eckert, Stephen; Abichandani, Rekha; Faderl, Stefan.

In: Journal of Clinical Oncology, Vol. 28, No. 4, 01.02.2010, p. 549-555.

Research output: Contribution to journalArticle

Kantarjian, HM, Erba, HP, Claxton, D, Arellano, M, Lyons, RM, Kovascovics, T, Gabrilove, J, Craig, M, Douer, D, Maris, M, Petersdorf, S, Shami, PJ, Yeager, AM, Eckert, S, Abichandani, R & Faderl, S 2010, 'Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors', Journal of Clinical Oncology, vol. 28, no. 4, pp. 549-555. https://doi.org/10.1200/JCO.2009.23.3130
Kantarjian, Hagop M. ; Erba, Harry P. ; Claxton, David ; Arellano, Martha ; Lyons, Roger M. ; Kovascovics, Tibor ; Gabrilove, Janice ; Craig, Michael ; Douer, Dan ; Maris, Michael ; Petersdorf, Stephen ; Shami, Paul J. ; Yeager, Andrew M ; Eckert, Stephen ; Abichandani, Rekha ; Faderl, Stefan. / Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 4. pp. 549-555.
@article{89132b094b874a24acf659ebed0526de,
title = "Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors",
abstract = "Purpose: This phase II study assessed clofarabine monotherapy in older adults (≥ 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. Patients and Methods: Clofarabine was administered intravenously for 5 days at 30 mg/m2/d during induction and 20 mg/m2/d during reinduction/consolidation (six cycles maximum). The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Results: In 112 evaluable patients who were treated (median age, 71 years; range, 60 to 88 years), the ORR was 46{\%} (38{\%} CR, 8{\%} CRp). ORR by unfavorable prognostic factor was 39{\%} for patients ≥ 70 years of age; 32{\%} for Eastern Cooperative Oncology Group (ECOG) performance status 2; 51{\%} for antecedent hematologic disorder; 54{\%} for intermediate karyotype; 42{\%} for unfavorable karyotype; and 48{\%}, 51{\%}, and 38{\%} for one, two, and three risk factors, respectively. The median disease-free survival was 37 weeks (95{\%} CI, 26 to 56 weeks). Median duration of remission was 56 weeks (95{\%} CI, 33 to not estimable). The estimated median overall survival was 41 weeks (95{\%} CI, 28 to 53 weeks) for all patients, 59 weeks for patients with CR/CRp, and 72 weeks for patients with CR. The 30-day all-cause mortality was 9.8{\%}. The most common non-laboratory drug-related toxicities (≥ 20{\%} patients) were nausea, febrile neutropenia, vomiting, diarrhea, rash, and fatigue. Conclusion: Clofarabine is an active agent with acceptable toxicity in patients age 60 years or older with untreated AML who have at least one unfavorable prognostic factor. ORR did not seem affected by the presence of multiple unfavorable prognostic factors.",
author = "Kantarjian, {Hagop M.} and Erba, {Harry P.} and David Claxton and Martha Arellano and Lyons, {Roger M.} and Tibor Kovascovics and Janice Gabrilove and Michael Craig and Dan Douer and Michael Maris and Stephen Petersdorf and Shami, {Paul J.} and Yeager, {Andrew M} and Stephen Eckert and Rekha Abichandani and Stefan Faderl",
year = "2010",
month = "2",
day = "1",
doi = "10.1200/JCO.2009.23.3130",
language = "English (US)",
volume = "28",
pages = "549--555",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

AU - Kantarjian, Hagop M.

AU - Erba, Harry P.

AU - Claxton, David

AU - Arellano, Martha

AU - Lyons, Roger M.

AU - Kovascovics, Tibor

AU - Gabrilove, Janice

AU - Craig, Michael

AU - Douer, Dan

AU - Maris, Michael

AU - Petersdorf, Stephen

AU - Shami, Paul J.

AU - Yeager, Andrew M

AU - Eckert, Stephen

AU - Abichandani, Rekha

AU - Faderl, Stefan

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Purpose: This phase II study assessed clofarabine monotherapy in older adults (≥ 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. Patients and Methods: Clofarabine was administered intravenously for 5 days at 30 mg/m2/d during induction and 20 mg/m2/d during reinduction/consolidation (six cycles maximum). The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Results: In 112 evaluable patients who were treated (median age, 71 years; range, 60 to 88 years), the ORR was 46% (38% CR, 8% CRp). ORR by unfavorable prognostic factor was 39% for patients ≥ 70 years of age; 32% for Eastern Cooperative Oncology Group (ECOG) performance status 2; 51% for antecedent hematologic disorder; 54% for intermediate karyotype; 42% for unfavorable karyotype; and 48%, 51%, and 38% for one, two, and three risk factors, respectively. The median disease-free survival was 37 weeks (95% CI, 26 to 56 weeks). Median duration of remission was 56 weeks (95% CI, 33 to not estimable). The estimated median overall survival was 41 weeks (95% CI, 28 to 53 weeks) for all patients, 59 weeks for patients with CR/CRp, and 72 weeks for patients with CR. The 30-day all-cause mortality was 9.8%. The most common non-laboratory drug-related toxicities (≥ 20% patients) were nausea, febrile neutropenia, vomiting, diarrhea, rash, and fatigue. Conclusion: Clofarabine is an active agent with acceptable toxicity in patients age 60 years or older with untreated AML who have at least one unfavorable prognostic factor. ORR did not seem affected by the presence of multiple unfavorable prognostic factors.

AB - Purpose: This phase II study assessed clofarabine monotherapy in older adults (≥ 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. Patients and Methods: Clofarabine was administered intravenously for 5 days at 30 mg/m2/d during induction and 20 mg/m2/d during reinduction/consolidation (six cycles maximum). The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Results: In 112 evaluable patients who were treated (median age, 71 years; range, 60 to 88 years), the ORR was 46% (38% CR, 8% CRp). ORR by unfavorable prognostic factor was 39% for patients ≥ 70 years of age; 32% for Eastern Cooperative Oncology Group (ECOG) performance status 2; 51% for antecedent hematologic disorder; 54% for intermediate karyotype; 42% for unfavorable karyotype; and 48%, 51%, and 38% for one, two, and three risk factors, respectively. The median disease-free survival was 37 weeks (95% CI, 26 to 56 weeks). Median duration of remission was 56 weeks (95% CI, 33 to not estimable). The estimated median overall survival was 41 weeks (95% CI, 28 to 53 weeks) for all patients, 59 weeks for patients with CR/CRp, and 72 weeks for patients with CR. The 30-day all-cause mortality was 9.8%. The most common non-laboratory drug-related toxicities (≥ 20% patients) were nausea, febrile neutropenia, vomiting, diarrhea, rash, and fatigue. Conclusion: Clofarabine is an active agent with acceptable toxicity in patients age 60 years or older with untreated AML who have at least one unfavorable prognostic factor. ORR did not seem affected by the presence of multiple unfavorable prognostic factors.

UR - http://www.scopus.com/inward/record.url?scp=77449159668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449159668&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.23.3130

DO - 10.1200/JCO.2009.23.3130

M3 - Article

C2 - 20026805

AN - SCOPUS:77449159668

VL - 28

SP - 549

EP - 555

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -